Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (unaudited)

v3.22.1
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net loss $ (5,936) $ (4,904)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 174 202
Stock-based compensation 424 384
Non-cash interest expense 151 46
Non-cash advertising expense 150
Non-cash portion of loss on debt extinguishment 161
Right of use asset amortization 165
Provision for bad debt 12
Deferred rent 43
Changes in operating assets and liabilities:    
Accounts receivable 2,956 (1,188)
Prepaid expenses and other current assets 38 19
Accounts payable 37 783
Accrued expenses and other current liabilities (1,169) (782)
Deferred revenue (977) (64)
Lease liability (184)
Customer deposits
Net cash used in operating activities (4,159) (5,300)
Cash flows from investing activities:    
Purchase of property and equipment (453) (157)
Net cash used in investing activities (453) (157)
Cash flows from financing activities:    
Proceeds from loan 15,000
Payment to unaccredited investors of Augmedix Operating Corporation (21)
Repayment of notes payable (12,966)
Payment of financing costs (195)
Proceeds from exercise of common stock warrants 4
Proceeds from exercise of stock options 13
Net cash provided by financing activities 13 1,822
Effect of exchange rate changes on cash and restricted cash (4) (1)
Net decrease in cash and restricted cash (4,603) (3,636)
Cash and restricted cash at beginning of period 41,587 22,973
Cash and restricted cash at end of period 36,984 19,337
Supplemental disclosure of cash flow information:    
Cash paid during the period for interest 450 393
Cash paid during the period for income taxes 13
Supplemental schedule of non-cash investing and financing activities:    
Adoption of ASC 842 new lease standard 2,599
Fair value of warrants issued in connection with loan 395
Financing costs in accrued expenses $ 37